celecoxib has been researched along with Arterial Obstructive Diseases in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Celecoxib is a potential inhibitor of neointimal formation by blocking injury-induced Akt activation." | 5.32 | Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling. ( Jeon, SI; Kim, HS; Kim, SH; Lee, MM; Oh, BH; Park, KW; Park, YB; Walsh, K; Yang, HM; You, HJ; Youn, SW, 2004) |
| "Celecoxib is a potential inhibitor of neointimal formation by blocking injury-induced Akt activation." | 1.32 | Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling. ( Jeon, SI; Kim, HS; Kim, SH; Lee, MM; Oh, BH; Park, KW; Park, YB; Walsh, K; Yang, HM; You, HJ; Youn, SW, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, HM | 1 |
| Kim, HS | 1 |
| Park, KW | 1 |
| You, HJ | 1 |
| Jeon, SI | 1 |
| Youn, SW | 1 |
| Kim, SH | 1 |
| Oh, BH | 1 |
| Lee, MM | 1 |
| Park, YB | 1 |
| Walsh, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00500279] | Phase 4 | 900 participants (Anticipated) | Interventional | 2006-11-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for celecoxib and Arterial Obstructive Diseases
| Article | Year |
|---|---|
Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling.
Topics: Animals; Apoptosis; Arterial Occlusive Diseases; Celecoxib; Cell Proliferation; Cell Survival; Cyclo | 2004 |